172 filings
ARS
2023 FY
JSPR
Jasper Therapeutics Inc
22 Apr 24
Annual report to shareholders
1:53pm
DEFA14A
JSPR
Jasper Therapeutics Inc
22 Apr 24
Additional proxy soliciting materials
1:37pm
DEF 14A
JSPR
Jasper Therapeutics Inc
Definitive proxy
22 Apr 24
1:13pm
S-8
JSPR
Jasper Therapeutics Inc
5 Mar 24
Registration of securities for employees
4:52pm
10-K
2023 FY
JSPR
Jasper Therapeutics Inc
Annual report
5 Mar 24
4:02pm
8-K
20nd26a gaub7er41j
4 Mar 24
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
7:40am
424B5
phwoqzwf6bp
7 Feb 24
Prospectus supplement for primary offering
12:00am
8-K
6h72gm y6
6 Feb 24
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock
9:07am
8-K
wm9a cquufq
4 Jan 24
Material Modifications to Rights of Security Holders
6:04am
8-K
8557tfuyu7vf 7b49xfw
2 Jan 24
Jasper Therapeutics, Inc. Announces Reverse Stock Split
8:05am
8-K
lvai5hhm0
20 Dec 23
Submission of Matters to a Vote of Security Holders
6:06am
8-K
cggqbq2pxfdfdzw9k82
9 Nov 23
Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
8:05am
8-K
sjwtwf wa60
1 Nov 23
Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors
8:00am
8-K
zkq6g
20 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6:04am
8-K
zx1bcq8r4nnfmf5 2t5h
10 Oct 23
Regulation FD Disclosure
7:00am
8-K
yt2u6
10 Oct 23
Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria
6:19am
8-K
lxnf3c
25 Sep 23
Jasper Therapeutics Appoints Herb Cross as Chief Financial Officer
8:00am